3d rendering of close up view of drug molecules inside of nanoparticles

CREDIT: iStock.com/Love Employee

Nanoworx announces nanomedicine development and optimization services!

Operational scale-up accelerates global growth strategy to increase regional access and technical support
| 1 min read

Nanoworx B.V., a Contract Research Organization specializing in nanomedicine, is thrilled to announce the launch of its comprehensive service portfolio for academic and industry partners. Based in Eindhoven, Netherlands, Nanoworx leverages state-of-the-art equipment and deep expertise to advance the design, optimization, and scaling of nanoparticle-based solutions.

The company offers four core services tailored to client needs:

  • Nanoparticle design and prototyping
  • Nanomedicine high-throughput library construction and screening
  • Nanomedicine production at scale
  • In vitro assay testing

These services are fully customizable, supporting clients at any stage of nanomedicine development, from early exploration to advanced platform optimization.

According to Dr. Makri-Pistikou, Co-founder and COO at Nanoworx: “With our unique knowledge and highly-skilled team, Nanoworx empowers clients to unlock the transformative potential of nanomedicine. We stand out by combining state-of-the-art facilities with a client-centric approach that builds lasting capabilities.” 

Meet Nanoworx at SLAS Europe 2025 in Hamburg, where they will showcase their capabilities at the Innovation AveNEW booth. For more details, visit www.nanoworx.nl or contact info@nanoworx.nl.

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue